> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Prospective AI Versioning Standard Needed: Post
- URL: https://www.fdaweb.com/prospective-ai-versioning-standard-needed-post/
- Published: 2026-04-29T12:00:00.000Z
- Updated: 2026-09-14T13:38:21.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161061

A *Clinical Trial Vanguard* online post explains the need for a prospective artificial intelligence (AI) versioning standard for investigational use. “Every model update deployed to a trial system should require a version identifier logged in the trial master file,” the [post](https://www.clinicaltrialvanguard.com/opinion/fda-real-time-clinical-trials-why-ai-systems-that-update-themselves-are-breaking-clinical-trial-design/?ref=fdaweb.com) says, “a documented assessment of whether the update constitutes a significant change under FDA’s investigational device change guidance, and a statistical impact analysis confirming that pre-specified endpoints remain interpretable under the updated model. That is not bureaucratic excess. It is the minimum evidentiary hygiene required to defend a primary endpoint in front of an FDA advisory committee.”

The post describes FDA’s 4/2026 [real-time clinical trial initiative](https://www.fda.gov/news-events/press-announcements/fda-announces-major-steps-implement-real-time-clinical-trials?ref=fdaweb.com) as “genuinely ambitious. The agency is signaling that it wants AI and data science integrated into trial infrastructure at the safety monitoring level, not just as an analysis tool, but as a live operational component. That posture is understandable given the evidence that traditional safety monitoring misses early signals that real-time AI surveillance could catch. But ambition and infrastructure are different things.”

The International Council on Harmonization M15 [framework](https://www.ich.org/news/harmonised-ich-m15-guideline-general-principles-model-informed-drug-development-adopted?ref=fdaweb.com) on model-informed drug development and FDA’s existing adaptive design guidance together provide the conceptual scaffolding for the needed guidance, the post says. What is missing, it adds is a sponsor-facing operational standard that specifies how to document AI model provenance within an eClinical system, how to trigger institutional review board notification when a model update affects patient-facing decision support, and how to handle retrospective sensitivity analyses when undisclosed updates are discovered during audit.

“FDA’s real-time clinical trial announcement of 4/28 is the starting gun, not the finish line,” the post concludes. “Sponsors who treat it as a permission slip to embed continuously updating AI into confirmatory trials without versioning controls will discover, at the worst possible moment — the complete response letter stage — that the trial they ran is not the trial the agency can evaluate. The algorithm kept learning. The protocol did not.”